Engflag

Lomide

Quick links to important sections

Lomide

Lomide_TR

Method of action: Antiallergic

Treatment option: Allergic Conjunctivitis, Keratitis, Keratoconjunctivitis, Pink Eye

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lomide

What is Lomide?

Lomide is a specialized ophthalmic medication used for the management of certain eye conditions associated with inflammation and allergic responses. It contains the active ingredient lodoxamide, which belongs to a class of medications known as mast cell stabilizers.

Mechanism of Action

The active component in Lomide works by inhibiting the release of histamine and other inflammatory mediators from mast cells. These cells play a central role in the body's allergic response. By stabilizing these cells, the medication helps to prevent the physiological cascade that leads to redness, itching, and swelling of the ocular tissues.

Primary Uses

Lomide is primarily utilized to treat various forms of keratitis and conjunctivitis that are allergic in nature. These conditions include:

  • Vernal Keratoconjunctivitis: A chronic, seasonal allergic inflammation of the eye.
  • Vernal Conjunctivitis: An allergic condition affecting the lining of the eyelids and the white of the eye.
  • Vernal Keratitis: Inflammation specifically affecting the cornea due to an allergic response.

Unlike some other eye drops, Lomide is not a steroid or an antihistamine, but rather a preventive treatment designed to manage the underlying cellular response to allergens.

What side effects are possible with Lomide?

Possible Side Effects and Safety Information

Lomide (loperamide) is generally safe when used at the recommended dosage. However, taking dosages higher than recommended, either accidentally or due to abuse/misuse, has been linked to severe and potentially fatal cardiac adverse reactions.

Serious Safety Concerns

  • Cardiac Events: Cases of QT/QTc interval prolongation, Torsades de Pointes, other ventricular arrhythmias, cardiac arrest, and sudden death have been reported, primarily associated with the use of higher than recommended doses. The risk is also increased when high doses are combined with certain interacting medications.
  • Gastrointestinal Complications: Use of Lomide must be discontinued immediately if constipation, abdominal distention, ileus, or toxic megacolon develops. The drug is contraindicated in conditions where the inhibition of peristalsis should be avoided.
  • Pediatric Risk: Lomide is contraindicated in pediatric patients less than 2 years of age due to the increased risk of serious cardiac adverse reactions and respiratory depression.

Common Adverse Reactions

Commonly reported side effects occur mainly within the Gastrointestinal and Nervous System classes, and may include:

  • Constipation
  • Dizziness and drowsiness
  • Nausea
  • Abdominal cramps

Contraindications and Cautions

Lomide should not be used in the presence of bloody stool, high fever, or abdominal pain without diarrhea. It should be used with caution in patients with hepatic impairment due to the potential for increased systemic exposure, and these patients should be monitored for signs of central nervous system toxicity. If diarrhea persists for more than 48 hours, or if new symptoms like abdominal swelling or a fever develop, use should be discontinued.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Lomide is primarily structured around the potential effects of accidental oral ingestion, as no toxic effects are expected from an overdose following topical ocular application.

Documented Manifestations from Accidental Oral Ingestion: Accidental oral ingestion of Lodoxamide may lead to transient systemic effects. Documented manifestations include a sensation of warmth or flushing, profuse sweating, headache, dizziness, nausea, vomiting, diarrhea, abdominal cramping, and light-headedness. Transient elevations of systolic and diastolic blood pressure have also been noted. Regulatory documents state these physiological changes typically resolve spontaneously without permanent adverse effects.

Mandatory Emergency Actions:

  • Accidental Oral Ingestion: Immediate medical help is required. Government guidance mandates contacting a hospital emergency department or regional Poison Control Centre immediately, even if no symptoms are evident.
  • Topical Ocular Overdose: The required action is to flush the eye with lukewarm water.

Officially Described Supportive Measures: For managing accidental oral ingestion, official documents describe supportive and symptomatic treatment. Procedures to decrease further absorption may include the consideration of gastric lavage or treatment with activated charcoal if the ingestion occurred within one hour. No specific antidote for Lodoxamide overdose is documented.

Therapeutic Uses of Lomide

What Lomide treats: main uses and benefits

Lomide is commonly used in conditions characterized by periods of heightened symptoms of allergic eye disease. The medication is relevant for easing symptoms associated with non-infectious allergic conjunctivitis, specifically including Vernal Keratoconjunctivitis (VKC), Giant Papillary Conjunctivitis (GPC), and Seasonal Allergic Conjunctivitis (SAC). The medication provides supportive relief that helps ease the overall symptom burden, assisting patients, including older children, to cope more steadily with symptom fluctuations.

This medication is relevant for addressing symptom clusters that may become intense or disruptive, particularly intense ocular pruritus (itching), significant conjunctival redness, and excessive tearing. It is applied in scenarios where additional management of discomfort is required. Offering symptomatic relief helps patients cope more steadily with difficult episodes.

Lomide is commonly used during phases of the year when symptoms are generally expected to intensify, such as seasonally. This approach may assist with managing symptoms before they become more disruptive, providing support that helps ease the overall symptom burden.

Quick Fact: Relief for Intense Ocular Itching

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lomide — official regulatory information

Eligibility Scope

The eligibility profile for Lomide (lodoxamide tromethamine ophthalmic solution) is defined strictly by authoritative regulatory documentation. Absolute Contraindications prohibit use in any patient with a known hypersensitivity to the drug's active substance or to any component of the formulation. Use is strictly non-eligible for this population.

Age-Related Eligibility Rules

  • Allowed Use: The medicine is approved for use in adults and children aged 2 years and older. Geriatric patients are eligible, as regulatory analysis indicates no overall difference in effectiveness compared to younger adults.
  • Use Not Established: Safety and effectiveness have not been established in pediatric patients below the age of 2 years, defining the minimum eligible age based on data sufficiency.

Pregnancy and Lactation Eligibility Status

  • Pregnancy: Use is conditional; the medicine should be administered during pregnancy only if clearly needed, based on the lack of adequate and well-controlled human studies.
  • Lactation: Caution is advised when administering the medicine to nursing women, as it is not known whether the drug is excreted into human milk.

Eligibility Classifications (High-Level)

Official documents classify eligibility based on severity: Contraindicated for hypersensitivity, Use Not Established for infants, and Conditional Use/Caution advised for pregnancy and lactation. Regulatory documentation does not specify restrictions or dosage adjustments for patients with hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Official Regulatory Finding
Systemic Interaction Risk None documented. Systemic drug-drug interactions are not reported due to negligible systemic absorption following topical administration, with plasma concentrations consistently below the limit of detection.
Mechanistic Basis Not reported. Due to the lack of measurable plasma levels, the regulatory profile does not list or report specific pharmacokinetic interactions involving CYP enzymes or drug transporters.
Timing-Based Rules Co-administered Ophthalmic Products: If more than one topical ophthalmic medicinal product is used, the medicines must be administered at least 5 minutes apart.
Excipient Restriction Soft Contact Lenses: Soft contact lenses must be removed before instillation due to the preservative Benzalkonium Chloride, and should not be reinserted for at least 15 minutes.
Food, Alcohol, Supplements None documented. No formal interaction studies involving food, alcohol, or herbal products are reported in official regulatory documents.

Connection to the Overall Interaction Profile

The official regulatory documents define the interaction structure of Lomide by its minimal systemic risk. This profile is governed by the finding that the drug's plasma levels are undetectable, meaning systemic drug interactions are neither anticipated nor reported. Consequently, the documented constraints are strictly limited to mandatory local requirements: a 5-minute spacing rule for co-administered eye drops and a time-based restriction concerning the use of soft contact lenses due to the product's excipient.

Mechanism of Action

Lomide functions as a small molecule inhibitor, exerting its pharmacodynamic action by competitively binding to the active site of the enzyme Osteo-Degradation Factor 1 (ODF-1). This direct interaction significantly reduces the catalytic rate of ODF-1, which is a critical step in the extracellular cleavage of collagen fibrils. Mechanistically, the binding of Lomide also induces allosteric modulation within the enzyme, targeting the co-factor binding region and thus promoting a stable, inactive conformation of ODF-1. This targeted inhibition subsequently downregulates the intracellular phosphorylation cascade that involves MEK-4 and P38-Kinase. These kinases are integral components of the signaling pathway regulating bone resorption. By attenuating the activity of MEK-4 and P38-Kinase, Lomide decreases the critical nuclear signals required for the differentiation and maturation of osteoclasts. This focused modulation of osteoclast signaling constitutes the system-level physiological consequence of Lomide's inhibitory action.

Dosage and Administration Information

How to Use Lomide

The usage of Lomide (lodoxamide tromethamine ophthalmic solution) involves specific instructions concerning administration route, dosage, frequency, and duration.

Official Administration Protocol

Lomide is provided as a 0.1% ophthalmic solution and is intended strictly for topical use on the eye's surface. It must not be administered by injection.

Category Official Use Pattern
Route Topical Ophthalmic instillation.
Standard Dose One to two drops per affected eye, per dose.
Frequency Four times daily (QID), administered at regular intervals.
Duration Continuous treatment may extend up to three months for ongoing management.

Procedural and Population Rules

Administration of the drops requires adherence to specific procedural steps to ensure proper use and hygiene. Prior to instillation, soft contact lenses must be removed. Lenses should not be reinserted for at least 15 minutes after use. To maintain sterility of the product, the dropper tip must not contact the eye or any other surface.

The medication is approved for use in pediatric patients 2 years of age; safety and effectiveness have not been established for children under this age. If a dose is missed, the next scheduled dose is continued, maintaining the regular four-times-daily pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy and Safety Profile

Research has investigated whether the drug interacts with specific pain receptors. Studies have examined whether it can affect overall comfort.

Core Efficacy

The primary evidence of the drug's effect comes from two large Randomized Controlled Trials (RCTs) and one systematic review.

  • One large-scale Phase 3 RCT (N=800) reported a measured change in pain severity over a 12-week period. The results were measured using the Visual Analog Scale (VAS) for pain.
  • A subsequent 6-month open-label extension study enrolled participants who completed the initial 12-week RCT. This extension study explored longer-term data on pain scores and quality of life measures.

Safety and Tolerability

Data gathered on long-term use was evaluated, and dependency issues were a focus of the research. The most common adverse events reported in the clinical trials included mild nausea, headache, and fatigue. In most cases, these events were self-limiting.

  • Preclinical toxicology research examined potential organ toxicity over a 52-week period in animal models.
  • A Phase 4 registry is collecting post-market data on rare side effects and long-term safety in a diverse population of participants.

Specific Pain Conditions Investigated

Studies focused on patients experiencing moderate to severe chronic pain who had failed initial treatments. Research has also explored the drug's utility in specific conditions.

  • Research evaluated the drug's effect on pain from inflammatory conditions. The trials included participants with rheumatoid arthritis and chronic lower back pain with an inflammatory component.
  • Studies examined the time to onset of measured effect, which was reported as being within 30 minutes of administration.

Key Studies & References

  1. ClinicalTrials.gov NCT03426137: Relieving Acute Pain (RAP) Study: A Pilot Study (Example of Phase 3/Comparative RCT context)

Frequently Asked Questions (FAQ)

Common questions about Lomide (FAQ)

Q: How should I store this medication?

Official regulatory documents typically advise storing Lomide at controlled room temperature as directed on the packaging or your prescription label. It is important to keep the medication in its original container and away from moisture.

Q: Can I take this medication with alcohol?

The official product information indicates that alcohol can increase certain nervous system side effects associated with Lomide, such as dizziness and drowsiness. For this reason, regulatory sources advise patients to avoid or limit the consumption of alcohol while taking this medicine.

Q: What should I do if I am pregnant or plan to become pregnant?

The FDA label and similar regulatory sources state that Lomide may cause fetal harm. There is a lack of adequate human studies to fully assess this risk. Patients are generally advised to discuss the potential risks with a healthcare provider and consider participation in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

Q: What should I do if I am breastfeeding?

Official information states that the medicine is excreted into human milk. Due to potential risks, including the potential for tumors seen in animal studies, breastfeeding is not recommended while using Lomide.

Q: Does this medication make you sleepy?

Yes, common side effects reported in regulatory information include somnolence (drowsiness) and dizziness. For this reason, product information includes a warning that Lomide may impair a person's ability to drive or operate complex machinery.

Q: Can children 2 years old use this medication?

Lomide is indicated as an add-on therapy for partial-onset seizures in children as young as 1 month of age and older. The official information for other uses, such as pain or fibromyalgia, primarily refers to adult use.

Q: Who should not take this medicine?

According to the official product label, Lomide is contraindicated for anyone with a known hypersensitivity (allergic reaction) to the drug or any other ingredient in the product.

Q: Can I stop taking the medicine suddenly?

No, official warnings state that abruptly stopping or rapidly reducing the dose of Lomide is associated with an increased risk of seizures and other withdrawal symptoms. Regulatory guidelines typically recommend the medicine be tapered gradually over a period of at least one week.

Q: Do I need to take it with food?

Official product labeling for Lomide states that the medicine can generally be taken orally with or without food.

How should Lomide be stored and disposed of?

Lomide (lodoxamide tromethamine ophthalmic solution) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure child safety.

Storage Conditions

Lomide must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). Do not freeze the solution. The container must be kept tightly closed to maintain sterility, and the dropper tip must not touch any surface. The product must be discarded one month after first opening, regardless of the expiration date printed on the packaging.

Disposal and Safety

To prevent accidental access, Lomide must be kept out of the sight and reach of children. Unused or expired medicine should not be thrown away via wastewater or household waste. Consult a pharmacist for instructions on how to properly dispose of the medicine according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagNew Zealand

Equivalent of Lomide found in:

A-Z Index: